Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer. - Kirane A; Toombs JE; Ostapoff K; Carbon JG; Zaknoen S; Braunfeld J; Schwarz RE; Burrows FJ; Brekken RA (Clinical cancer research : an official journal of the American Association for Cancer Research, 2012)